the impact of esas in lower-risk mds
Published 2 years ago • 46 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
2:37
esas for the management of lower-risk mds
-
1:59
the role of inflammatory signaling pathways in lower-risk mds
-
11:53
the optimal treatment of lower risk mds
-
1:20
the current standard of care for patients with lower-risk mds
-
1:14
real-world treatment patterns of patients with low-risk mds reinitiating esas
-
49:25
myelodysplastic syndrome (mds) and anemia
-
6:03
robin roberts, 'good morning america' host, discusses mds diagnosis: 'i'm going to beat this'
-
54:01
mds prognosis - understanding ipss and ipss-r scores 2018
-
11:33
treatment algorithm for low-risk mds
-
1:50
considerations for risk-adapted therapy in lower-risk mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
1:45
a phase ii study of elritercept for lower-risk mds
-
1:34
perspectives on the management of low and high-risk mds
-
1:16
state of the art: mds
-
1:32
next-generation sequencing for low-risk mds
-
3:15
mds: treating high and low-risk disease
-
2:06
understanding the role of inflammation and the immunome in mds pathophysiology
-
1:12
hypomethylating agents for low risk mds
-
1:27
key clinical trials in high-risk and low-risk mds
-
3:38
a new set of treatment options for low-risk mds
-
0:55
the unmet needs in low-risk mds
-
1:00
mds: what's the impact of early diagnosis?